Skip to content
Biodatica
Start free

AtlasMedx, Incorporated

Los Angeles, California

OncologyPhase II
Compare Sign in to watch

What changed

NIH R01 · $0.7M · Integrating Epigenetic Modulation into DNA Damage Repair

2mo agoGrant renewalMay 12, 2026Source filing (opens the source filing in a new tab)

Momentum

65no change

Momentum 65 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,496 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    R01 · $659k · non-dilutive

    Jun 6, 2022

    UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MUNSTER, PAMELA N. · NCI · award ends May 31, 2027 · Integrating Epigenetic Modulation into DNA Damage Repair

    NIH RePORTER · NIH RePORTER 11331241 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Jan 20, 2022

    Pancreatic Carcinoma · RECRUITING · sponsor: University of California, San Francisco · Pilot Study of Pancreatic Cancer Screening

    ClinicalTrials.gov · NCT05058846 (opens the source filing in a new tab)

  3. Trial

    PHASE1/PHASE2 registered

    Aug 12, 2020

    Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Prostate Cancer, Pancreatic Cancer · RECRUITING · sponsor: AtlasMedx, Incorporated · A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

    ClinicalTrials.gov · NCT04503265 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Jun 25, 2012

    Metastatic Solid Tumors · COMPLETED · sponsor: Pamela Munster · Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

    ClinicalTrials.gov · NCT01543763 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources